Poor survival rates in patients were associated with the increased expression of these genes across cancer types, such as IGF2BP1 (HR = 1.324527, P = 2.38E-06) in LUAD and IGF2BP2 (HR = 1.198617, P = 0.006603) and IGF2BP3 (HR = 1.570331, P = 0.000198) in LIHC. This evidence concerns the gene IGF2BP2 and cancer.